Addition of single-dose, maternal tenofovir and emtricitabine to reduce non-nucleoside reverse transcriptase inhibitor resistance mutations in the setting of zidovudine and nevirapine for prevention of mother-to-child HIV transmission
Phase of Trial: Phase II
Latest Information Update: 30 May 2012
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 30 May 2012 Additional lead trial center identified as reported by ClinicalTrials.gov.
- 16 Nov 2005 New trial record.